accounted for by an IGF-I deficiency; (b) both the rise in IGF-I and a fall in insulin contributed to the rise in IGFBP-1 after acute IGF-I administration; (c) prolonged IGF-I or GH treatment causes a persistent decline in IGFBP-1 concentration. In conclusion, IGF (3) . In some patients the molecular defect is in the extracellular part of the GH receptor (4, 5) , which is identical in structure to the GHbinding protein (6) and thus is absent in most LTD patients (7) . These defects prevent any GH activity, including the generation of IGF-I (8) .
The aim of the present study was to study the relationship between IGFBP-1, IGF-I and GH in extreme clinical conditions. We determined the circulating levels of IGFBP-1 in patients with LTD, growth hormone deficiency (GHD), and in children with growth retarda¬ tion without GHD 
Effect of IGF-I injection
After intravenous injection of IGF-I, serum IGF-I concen¬ tration increased in LTD patients 10-fold and remained elevated for the 120 min follow-up period (Fig. 4) Previous studies have demonstrated lower than nor¬ mal IGFBP-1 concentrations in acromegaly (26) , and a fall in IGFBP-1 concentration in infertile women during GH therapy (27) 
